Exact Sciences completed the acquisition of Ashion Analytics from The Translational Genomics Research Institute.

Exact Sciences, a provider of cancer screening and diagnostic tests, completed the acquisition of Ashion Analytics, a clinical genomics testing company, from The Translational Genomics Research Institute, a Phoenix, Arizona-based nonprofit organization. Financial terms were not disclosed. "With Ashion, we've added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensive genomic cancer tests available on the market today with GEM ExTra. This expertise will be integral in helping us extend our leadership in precision oncology and in serving more patients across the cancer continuum, including therapy selection and minimal residual disease testing," Kevin Conroy, Exact Sciences Chairman and CEO.